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The Bone & Joint Journal is keen on randomised clinical trials. The reason for this is 
straightforward. Randomisation is a simple and highly effective way of reducing the effects 
of ‘confounding factors’ in comparative research. Trauma and orthopaedic surgery has some 
of the most effective interventions in medicine. However, all surgical interventions are 
‘complex’ in that they have many interacting facets which each contribute to the overall 
result. The selection of patients, the preoperative pathway, the anaesthetic technique, the 
experience of the surgeon, the nursing and therapy staff, and even the hospital food, can all 
have an influence on the outcome. Any factor that is independently related to both the 
intervention and the outcome is called a ‘confounder’ (Fig. 1). Whilst some confounding 
variables can be identified and measured, such as the age of the patients, others may be 
unknown or difficult to measure, such as the influence of surgical expertise. Therefore, 
confounding is always a problem in trauma and orthopaedic research, even if we are able to 
match the patients taking part in a trial carefully. 
 
 
Figure 1. Researchers identify a strong association between grey hair and hip 
fracture. Patient age is independently associated with both grey hair colour, and 
hip fracture. Patient age is therefore a confounding variable. 
 
 
We have previously provided guidance on aspects of reporting randomised trials in The Bone 
& Joint Journal,1-3 and the overall quality of reporting is improving all the time. A new 
requirement of prospective registration of the details of trials will, hopefully, push us further 
in the right direction.4 However, there is still plenty of room for confusion. One common area 
of difficulty is the reporting of ‘efficacy’ versus ‘effectiveness’ randomised trials. 
What does this mean and why is the distinction important? 
Efficacy trials report the results of tightly defined interventions, provided to highly selected 
participants in optimal surroundings. They usually involve a single centre and, because of the 
highly controlled design, usually have smaller sample sizes. Such designs are often described 
as ‘experimental’. Efficacy trials provide estimates of the ‘best possible’ effect of an 
intervention. A good example is the recent trial from van der Woude et al.5 This exciting trial 
may represent a major step forward in the management and surgical approach to a common 
orthopaedic problem if, and only if, the results can be reproduced more broadly. 
Effectiveness trials seek to establish the effect of different interventions when they are 
delivered in the context of a whole healthcare system. In such studies the eligibility criteria 
are usually broader and the interventions take place in less controlled environments; thus, in 
any institution where the intervention may be delivered, by any team who are able to do so. 
Many surgeons, anaesthetists and therapists are typically involved in such trials, and they are 
usually multi-centre and involve many more patients. Effectiveness trials are designed to 
reflect how the intervention works in the real world context of the healthcare system in which 
it is tested. These designs are often termed ‘pragmatic’. A recent example is the Distal Radius 
Acute Fracture Fixation Trial,6,7 which investigated the use of locking plates compared with 
K-wires for the fixation of dorsally displaced fractures of the distal radius. Almost any adult 
patient with this fracture was eligible and over 200 surgeons took part in 18 centres of 
varying size and specialism. The trial was designed to replicate current practice across the 
NHS in the United Kingdom, and has subsequently been used to shape both practice and 
policy.8,9 
It is important to stress that neither type of design is correct or incorrect; both have a role in 
the research ‘pathway’. Efficacy (experimental) designs are often used early on in the 
implementation of a new intervention. Investigators seek to control as much of the design of 
the study as possible to provide evidence towards the best possible outcomes for the new 
intervention. These studies have the potential to change clinical practice, but can the results 
described in these experimental trials be reproduced in the real world? Effectiveness 
(pragmatic) trials are then warranted. Unfortunately, there are many examples where 
promising results described in the experimental setting do not translate well into the broader 
health service environment.10 
In reality, the difference between the design of an experimental and a pragmatic trial is not 
black and white. Pragmatism is a spectrum ranging from the first report of a new device by 
the design-surgeon in one centre with specific participants, through to the large, multicentre 
trials favoured by the makers of guidelines and policies. An understanding of the distinction 
between the designs of trials is particularly important for readers, in order to consider how 
best to apply the research findings. 
 
Guidance for potential authors 
If you are reporting an efficacy trial with an experimental design, tell us upfront. Describe 
your eligibility criteria in detail, tell us about the experience and involvement of the 
surgeon/centre providing the intervention and explain why you are using detailed, potentially 
complicated outcome tools. The reader will then understand the context of the trial and will 
be able to judge whether or not they can replicate these interventions in their own practice. It 
is always helpful if you report the limitations inherent in efficacy trials in the discussion 
section of your paper. Can these results be replicated elsewhere? Similarly, if you are 
reporting an effectiveness trial, and use the word pragmatic at the beginning of your report, 
the reader will know to expect broad eligibility criteria, many centres and surgeons and 
patient-focused outcome measures. The limitations section of the paper should then 
invariably reflect on how pragmatic the trial is. Does this trial really replicate clinical practice 
in your healthcare setting? 
We are, of course, delighted to receive both types of trial design at The Bone & Joint Journal. 
 
References: 
1. Costa ML, Stengel D, Griffin XL, Carey Smith R, Parsons N. Research methods and The Bone & 
Joint Journal. Bone Joint J 2013;95-B:2–3. 
2. Parsons N, Carey Smith R, Griffin XL, Stengel D, Costa ML. Research fraud and The Bone & Joint 
Journal. Bone Joint J 2013;95-B:866–867. 
3. Griffin XL, Parsons N, Smith RC, Stengel D, Costa ML. Intention-to-treat analyses for 
interventional studies. Bone Joint J 2013;95-B:1443–1444. 
4. Leopold SS, Swiontkowski M, Haddad FS. The Journal of Bone and Joint Surgery, The Bone & 
Joint Journal, and Clinical Orthopaedics and Related Research require prospective registration of 
randomised clinical trials. Bone Joint J 2016;98B:1571–1572. 
5. van der Woude JA, Wiegant K, van Heerwaarden RJ, et al. Knee joint distraction compared with 
total knee arthroplasty: a randomised controlled trial. Bone Joint J 2016;99-B:51–58. 
6. Costa ML, Achten J, Parsons NR, et al. Percutaneous fixation with Kirschner wires versus volar 
locking plate fixation in adults with dorsally displaced fracture of distal radius: randomised controlled 
trial. BMJ 2014;349:4807. 
7. Tubeuf S, Yu G, Achten J, et al. Cost effectiveness of treatment with percutaneous Kirschner wires 
versus volar locking plate for adult patients with a dorsally displaced fracture of the distal radius: 
analysis from the DRAFFT trial. Bone Joint J 2015;97-B:1082–1089. 
8. Costa ML, Jameson SS, Reed MR. Do large pragmatic randomised trials change clinical practice?: 
assessing the impact of the Distal Radius Acute Fracture Fixation Trial (DRAFFT). Bone Joint J 
2016;98-B:410–413. 
9. No authors listed. National Institute for Health and Care Excellence 
http://www.nice.org.uk/guidance/ng38 (date last accessed 16 December 2016). 
10. Vendittoli P- A, Roy A, Mottard S, et al. Metal ion release from bearing wear and corrosion with 
28 mm and large-diameter metal-on-metal bearing articulations: a follow-up study. J Bone Joint Surg 
[Br] 2010;92-B:12–19. 
 
Affiliations: 
(1) University of Oxford, 
NDORMS, Oxford Trauma, 
Kadoorie Centre, John Radcliffe 
Hospital, Oxford, OX3 7UD, UK. 
(2) University of Warwick, 
Statistics and Epidemiology, 
Warwick Medical School, 
Coventry CV4 7AL, UK. 
(3) University of Liverpool, 
Institute of Translational 
Medicine, Easton Rd, Liverpool 
L12 2AP, UK. 
 
